Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Microsatellite Instability 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 24Nivolumab 15Magnetic Resonance Spectroscopy 7Ipilimumab 6avelumab 5atezolizumab 5Specimen Handling 5Docetaxel 4lenvatinib 3durvalumab 3Paclitaxel 3Cyclophosphamide 3Carboplatin 3fludarabine 2cabozantinib 2aldesleukin 2Interleukin-2 2Fluorodeoxyglucose F18 2FAPI-46 2zanidatamab 1veliparib 1tislelizumab 1spartalizumab 1soluble LAG-3 protein, human 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Carboxylesterase × Gynecologic × Clear all
NCT04106167 2023-09-21

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Fate Therapeutics

Terminated
20 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡